Delivery Order SPE2DB22D3004-SPE2DB24FRY03

Award Date 9/24/24
Potential Completion Date 9/25/24
Potential Value $6.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Belsomra 20 mg tablets, a prescription medication. The fixed-price contract has a ceiling value of $1,056.52 and runs through March 2025. There is no set-aside designation for this open competition award. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $1,058.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the prescription medication Belsomra 10 mg tablets, with a performance period through April 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp under the DLA Troop Support Medical Indefinite Delivery Contract (IDC). The contract, valued at up to $999,999,999 through December 2025, provides a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. This specific delivery order, valued at $1,216.11, is for the drug Belsomra 10mg tablets. There is no set-aside designation...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award, valued at $1,351.63, is for the delivery of the prescription medication Belsomra 20 mg tablets. The contract is a Firm Fixed Price Delivery Order, with a period of performance through May 1, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Belsomra 10 mg tablets. The firm-fixed-price contract has a ceiling value of $1,179.37 and a completion date of August 13, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide the specified medication to support federal healthcare programs and services. The contract is not set-aside and is part of a larger Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,290.36, is for the supply of the prescription medication Belsomra 20 mg tablets. It is a firm fixed-price, non-set-aside contract with a performance period through May 2025. AmerisourceBergen, as the prime contractor, will be responsible for delivering the pharmaceutical product to the government. This order is part of a...
This is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,390.28 firm fixed-price contract is for the supply of Belsomra 10mg tablets, a prescription medication used to treat insomnia. The award is part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BELSOMRA 20 MG TABLET 30S, a medication product. The contract has a firm fixed price, ceiling value of $1,357.14, and a performance period extending through June 12, 2025. This delivery order is not set aside and was competitively awarded. AmerisourceBergen Drug Corp...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Firm Fixed Price Delivery Order valued at $1,527.84 for the supply of 4565333163 - BELSOMRA 20 MG TABLET 30S. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical on August 2, 2024 and has an ultimate completion date of August 5, 2024. This contract is not a set-aside. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts...
This federal contract award is for the delivery of Belsomra 20 mg tablets, a prescription medication, to the Defense Logistics Agency (DLA). The $1,433.44 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 21, 2025, with a completion date of February 24, 2025. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB24FRY03
    Delivery Order

This contract award to AmerisourceBergen Drug Corp, a major pharmaceutical supplier, is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract valued at up to $999,999,999 through December 2025. It is for the supply of the prescription medication Belsomra 10 mg tablets in quantities of 30's, at a ceiling value of $6,078.50. The contract has a final completion date of September 25, 2024. No set-aside designation is noted. This award supports the DLA's role in providing essential pharmaceutical products to military treatment facilities and other federal healthcare providers.

Generated 12/24/24, 9:40 AM